Keywords: fda, panel, backs, cellcept, acute, rejection, syntex
FDA Panel Backs Cellcept For Acute Rejection
Article | 10 April 1995
Syntex' new-generation immunosuppressant drug, Cellcept (mycophenolate mofetil), should be approved for administration with Sandoz' Sandimmun/Neoral (ciclosporin) and corticosteroids for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
